

January 2025 Content Release Notes

Jan. 30, 2025

Contents

Clinical Profile Documentation	2
Additions.....	2
Updates	4
Lab Analytes & Panels	4
Additions.....	4
Medications	9
Additions.....	9
Updates	10
Regimen Library.....	10
Additions.....	10
Updates	12
Renames	13
Billing & HCPCS Codes	13
Updates	13

Clinical Profile Documentation

Additions

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses.

AKT1 status has been updated for **Breast Cancer** with the following documentation points:

- Mutation
- Wild type
- Unknown
- Other non-actionable finding

BRAF V600E status has been updated for **Colon Cancer, Lung Cancer, Non-Small Cell (NSCLC), and Rectal Cancer** with the following documentation points:

- V600E mutation
- Other V600 mutation
- Wild type
- Unknown
- Other non-actionable finding

BRAF V600E status has been updated for **Bile Duct Cancers (Parent), Esophageal Cancer (Parent), Fallopian Tube Cancer, Gastric Cancer, Neuroendocrine Tumor, Carcinoid (Parent), Ovarian and Primary Peritoneal Cancer, and Pancreatic Cancer** with the following documentation points:

- V600E mutation
- Wild type
- Unknown
- Other non-actionable finding

BRAF V600 status has been updated for **Melanoma, Skin** with the following documentation points:

- V600 mutation
- Wild type
- Other mutation of fusion
- Unknown
- Other non-actionable finding

Estrogen receptor 1 (ESR1) mutation has been updated for **Breast Cancer** with the following documentation points:

- Mutation
- Wild type
- Other non-actionable finding
- Unknown

Estrogen receptor 1 (ESR1) status after 1st line+ endocrine therapy (NCCN recommends re-testing at progression following prior lines of endocrine therapy) has been updated for **Breast Cancer** with the following documentation points:

- Mutation
- Wild type
- Other non-actionable finding
- Unknown

Estrogen receptor 1 (ESR1) status after 2nd line+ endocrine therapy (NCCN recommends re-testing at progression following prior lines of endocrine therapy) has been updated for **Breast Cancer** with the following documentation points:

- Mutation
- Wild type
- Other non-actionable finding
- Unknown

HER2 by ISH or NGS is now available for **Pancreatic Cancer** with the following documentation points:

- Positive
- Negative
- Unknown

KIT status has been updated for **Gastrointestinal Stromal Tumor (Parent)** with the following documentation points:

- Mutation
- Wild type
- Other non-actionable finding
- Unknown

NRG1 fusion status is now available for **Lung Cancer, Non-Small Cell (NSCLC)** with the following documentation points:

- Positive
- Negative
- Unknown
- Other non-actionable finding

PIK3CA status has been updated for **Breast Cancer** with the following documentation points:

- Mutation
- Wild type
- Unknown

PTEN alteration status has been updated for **Breast Cancer** with the following documentation points:

- Positive
- Negative
- Unknown

Updates

Curbside Connect with Dr. David Andorsky is no longer available for scheduling for **CLL**.

Insufficient tissue is no longer available for documentation for **ALK, PD-L1, or ROS1 gene** for **Non-small cell lung cancer**.

Lab Analytes & Panels

Additions

- (CFF-MA) citrated functional fibrinogen - MA, mm
- (CK-LY30) citrated kaolin - lysis 30 min after MA, %
- (CK-R) citrated kaolin - reaction time, min
- (CRT-MA) citrated rapid TEG - MA, mm
- BK virus DNA, quant PCR, urine, Log IU/mL

- Blasts, Absolute, %
- Blasts, Absolute, cells/uL
- Caris MI cancer seek (CMI024) panel
- Caris MI cancer seek + IHCs and other tests by tumor type (CMI025) panel
- CD4 helper, absolute, /uL
- CHEK2 panel
- Chlorpropamide, mcg/mL
- Citrated rapid TEG with lysis panel
- CKMB Panel
- ELANE panel
- EPCAM;MLH1 panel
- Ferritin, IBC, Hgb
- Fya/Fyb RBC antigen typing panel
- Glimepiride, ng/mL
- Glipizide, ng/mL
- Glyburide, ng/mL
- HIV Ab/p24 Ag with reflex panel
- HLA Ab identification class I high resolution panel
- HLA Ab identification class II high resolution panel
- HLA class I Ab interpretation
- HLA class II antibody interpretation
- Hypoglycemia(sulfonylureas), panel
- Invitae add-on genes with variable presentation panel
- Invitae add-on preliminary-evidence genes for congenital cataracts + invitae cataracts panel
- Invitae agammaglobulinemia panel
- Invitae amyotrophic lateral sclerosis with c9orf72 panel
- Invitae arrhythmia and cardiomyopathy comprehensive panel
- Invitae basal cell nevus syndrome panel
- Invitae basal cell nevus syndrome panel w/add-on preliminary-evidence gene
- Invitae bone marrow failure syndromes panel
- Invitae bone marrow failure syndromes panel w/add-on preliminary-evidence genes
- Invitae BRCA 1/2 panel
- Invitae BRCA 1/2 reflex to common hercan panel
- Invitae BRCA 1/2 reflex to multi-cancer panel
- Invitae BRCA1 and BRCA2 stat panel
- Invitae breast hereditary cancer panel
- Invitae cancer screen panel

- Invitae carney complex test
- Invitae chronic pancreatitis panel
- Invitae colorectal cancer guidelines-based panel
- Invitae common hereditary cancers + RNA panel
- Invitae common variable immunodeficiency panel
- Invitae comprehensive lysosomal storage disorders panel w/add-on adult-onset neuronal ceroid lipofuscinosis genes
- Invitae connective tissue disorders panel
- Invitae constitutional mismatch repair-deficiency panel
- Invitae diamond-blackfan anemia panel
- Invitae diamond-blackfan anemia panel w/add-on preliminary-evidence genes
- Invitae DNA damage repair panel
- Invitae ectodermal dysplasia and related disorders panel
- Invitae ehlers-danlos syndrome panel
- Invitae F2 panel
- Invitae familial gastrointestinal stromal tumor syndrome panel
- Invitae family variant testing panel
- Invitae fanconi anemia panel
- Invitae fanconi anemia panel w/add-on preliminary-evidence genes
- Invitae gaucher common variants test panel
- Invitae hereditary breast and gyn cancers guidelines-based panel
- Invitae hereditary breast and gyn cancers panel
- Invitae hereditary breast and gyn cancers panel w/add-on preliminary-evidence genes
- Invitae hereditary breast cancer guidelines-based panel
- Invitae hereditary breast cancer panel w/add-on preliminary-evidence genes
- Invitae hereditary breast cancer stat panel
- Invitae hereditary breast cancer stat panel w/add-on breast cancer stat genes
- Invitae hereditary colorectal cancer panel
- Invitae hereditary colorectal cancer panel w/add-on preliminary-evidence genes
- Invitae hereditary diffuse gastric cancer syndrome panel
- Invitae hereditary diffuse gastric cancer syndrome panel + invitae lynch syndrome panel + invitae multi-cancer panel
- Invitae hereditary gastric cancer panel
- Invitae hereditary hemorrhagic telangiectasia and vascular panel
- Invitae hereditary hyperparathyroidism panel
- Invitae hereditary hyperparathyroidism panel w/add-on preliminary-evidence genes
- Invitae hereditary lymphoma panel

- Invitae hereditary lymphoma panel w/add-on preliminary-evidence genes for lymphoma
- Invitae hereditary nervous system/brain cancer panel
- Invitae hereditary nervous system/brain cancer panel w/add-on preliminary-evidence genes
- Invitae hereditary neuroendocrine tumors and adrenocortical carcinoma panel
- Invitae hereditary neuroendocrine tumors and adrenocortical carcinoma panel w/add-on preliminary-evidence genes
- Invitae hereditary pancreatic cancer panel
- Invitae hereditary pancreatic cancer panel w/add-on chronic pancreatitis genes
- Invitae hereditary pancreatic cancer panel w/add-on preliminary-evidence genes
- Invitae hereditary paraganglioma-pheochromocytoma panel
- Invitae hereditary paraganglioma-pheochromocytoma panel w/add-on preliminary-evidence genes
- Invitae hereditary pediatric solid tumors panel
- Invitae hereditary pediatric solid tumors panel w/add-on preliminary-evidence genes
- Invitae hereditary prostate cancer panel
- Invitae hereditary prostate cancer panel w/add-on preliminary-evidence genes
- Invitae hereditary renal/urinary tract cancers panel
- Invitae hereditary renal/urinary tract cancers panel w/add-on preliminary-evidence genes
- Invitae hereditary sarcoma panel
- Invitae hereditary sarcoma panel w/add-on preliminary-evidence genes
- Invitae hereditary skin cancer panel
- Invitae hereditary skin cancer panel w/add-on cyld cutaneous syndrome gene
- Invitae hereditary skin cancer panel w/add-on preliminary-evidence genes
- Invitae hereditary thyroid cancer panel
- Invitae hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) test panel
- Invitae hereditary wilms tumor panel
- Invitae hereditary wilms tumor panel w/add-on preliminary-evidence gene for wilms tumor
- Invitae hypertrophic cardiomyopathy panel
- Invitae inherited platelet disorders including thrombocytopenia panel
- Invitae iron related disorders including anemia panel + invitae multi-cancer panel + invitae brca1/2 panel
- Invitae juvenile polyposis syndrome panel
- Invitae melanoma-pancreatic cancer syndrome panel
- Invitae multiple endocrine neoplasia type 1 test + invitae multiple endocrine neoplasia type 2 test panel
- Invitae multiple endocrine neoplasia type 2 test + invitae multiple endocrine neoplasia type 1 test panel

- Invitae myelodysplastic syndrome/leukemia panel
- Invitae myelodysplastic syndrome/leukemia panel w/add-on preliminary-evidence genes
- Invitae neurofibromatosis type 2 test
- Invitae phagocytic disorders including neutropenia panel
- Invitae pyruvate metabolism and related disorders panel
- Invitae retinoblastoma test + invitae multi-cancer panel
- Invitae rhabdoid tumor predisposition syndrome panel
- Invitae telomere biology disorders panel
- Invitae telomere biology disorders panel w/add-on preliminary-evidence genes
- Invitae thyroid cancer panel
- Lactoferrin, stool, quant, ug/mL
- Manganese, S, ng/mL
- Metamyelocytes, absolute, %
- Metamyelocytes, absolute, cells/uL
- MPN mini profile cells analyzed
- MPN mini profile cells counted
- MPN mini profile fish result
- MPN mini profile interpretation
- MPN mini profile specimen type
- MPN mini profile, panel
- MSH6 Del/Dup
- Myelocytes, absolute, %
- Myelocytes, absolute, cells/uL
- Nateglinide, mcg/mL
- OSA pan heme fusion
- Peripheral blood smear interpretation
- Pharyngeal gonorrhea/chlamydia by PCR panel
- Phosphatidylethanol
- Pioglitazone, ng/mL
- Promyelocytes, absolute, %
- Promyelocytes, absolute, cells/uL
- Protein S screen panel
- Protein S screen, %
- RBC morphology
- Rectal gonorrhea/chlamydia by PCR panel
- Repaglinide, ng/mL
- Riskguard hereditary cancer test panel

- Rosiglitazone, ng/mL
- Tempus xT CDx (DNA only) with matched normal/tumor and normal panel
- Tempus xT CDx (DNA only) without matched normal - tumor only panel
- Tempus xT CDx (DNA) & xR (RNA) - solid tumor panel
- Tempus xT CDx (DNA) & xR (RNA) - solid tumor/normal panel
- Tolazamide, mcg/mL
- Tolbutamide, mcg/mL
- Transglutaminase, IgA, Ab, ELU/mL
- Transglutaminase, IgG, Ab panel
- Transglutaminase, IgG, Ab, ELU/mL
- Trofile(R)
- Urine cell casts, /hpf
- Urine unknown casts, /hpf
- Urine unknown crystal, /hpf

Medications

Additions

- APVO436 invest IV
- BMS-986489 invest or Atezolizumab invest IV
- BNT323/DB-1303 invest IV
- Compound Estriol Vaginal Cream w/ Testosterone
- Compound Lidocaine-Sodium Bicarbonate Intravesical
- Compound Pregnenolone
- Compound Progesterone
- CRB-601 invest IV
- DHEA Vaginal Cream
- Estriol Vaginal Cream
- MK-2140 invest IV
- S095018 invest IV
- S095024 invest IV
- SR-8541A invest Oral
- Syringe with needle 1 mL 31 gauge x 5/16" (Send as RX)
- TORL-1-23 invest IV
- TSC-200-A0201 invest IV
- TSC-201-B0702 invest IV

- TSC-203-A0201 invest IV
- TSC-204-A0101 invest IV
- TSC-204-A0201 invest IV
- TSC-204-C0702 invest IV
- XL-092 invest Oral
- Zanzalintinib invest (XL-092 invest Oral)
- Zilovetamab Vedotin invest (MK-2140 invest IV)

Updates

Medication	Update
AO-252 invest Oral	New form available: 40 mg capsule
ASP1002 invest IV	New form available: 50 mg/10 mL (5 mg/mL) solution
BT8009 invest IV	New synonym available: Zelenectide pevedotin invest
MK-1026 invest Oral Nemtabrutinib invest (MK-1026 invest Oral)	New forms available: • 45 mg tablet • 65 mg tablet

Regimen Library

Additions

Regimen Name	Diagnosis
Abemaciclib + Fulvestrant + Trastuzumab Q21D (Trastuzumab only)	Breast Cancer
Abemaciclib + Fulvestrant + Trastuzumab Q28D IV (Abemaciclib + Fulvestrant only)	Breast Cancer

Regimen Name	Diagnosis
Amifampridine Q30D (Lambert-Eaton Myasthenic Syndrome)	All Problems
Atezolizumab IV + Bevacizumab + Paclitaxel + Carboplatin Q21D (Cervical)	Cervical Cancer
Atezolizumab IV + Bevacizumab + Paclitaxel + Cisplatin Q21D (Cervical)	Cervical Cancer
Bendamustine D1,2 Q28D	Lymphoma, Hodgkin
Brentuximab vedotin + Lenalidomide + Rituximab IV Q21D	Lymphoma, Non-Hodgkin (NHL)
Carboplatin + Paclitaxel Q7D Induction fb Cisplatin + XRT Q7D (Cervical)	Cervical Cancer
Gemcitabine + Oxaliplatin (GemOx) C1 D2 fb C3-8 D1 + Obinutuzumab D1 fb Glofitamab-gxbm (Columvi) D8,15 fb D1 Q21D	Lymphoma, Non-Hodgkin (NHL)
Inavolisib + Palbociclib D1-21 + Fulvestrant + Goserelin Q28D	Breast Cancer
Inavolisib + Palbociclib D1-21 + Fulvestrant + Leuprolide Q28D	Breast Cancer
Pembrolizumab + Docetaxel + Carboplatin Q21D (Neoadjuvant Breast)	Breast Cancer
Polatuzumab Vedotin D1 + Mosunetuzumab-axgb (Lunsumio) D1,8,15 fb D1 Q21D	Lymphoma, Non-Hodgkin (NHL)
Zanidatamab-hrii Q14D	Bile Duct Cancer

Regimen Name	Diagnosis
Zenocutuzumab-zbco D1,15 Q28D	Pancreatic Cancer, Carcinoid/Neuroendocrine, Lung Cancer, Non-small Cell (NSCLC)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Cervical Cancer
- Colon Cancer
- Esophageal Cancer (Parent)
- Gastric Cancer
- Hepatocellular Carcinoma (HCC)
- Leukemia, Acute Lymphocytic (ALL)
- Lung Cancer, Non-small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Hodgkin (HL)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Melanoma, Uvea, Ciliary Body/Choroid
- Melanoma, Uvea, Iris
- Multiple Myeloma (MM)
- Myelodysplastic Syndrome (MDS)
- Neuroendocrine Tumor, Carcinoid (Parent)
- Pancreatic Cancer
- Pancreatic Cancer, Carcinoid/Neuroendocrine
- Rectal Cancer
- Sarcoma, Soft Tissue (Parent)
- Solid Tumors (Parent) (including HL/NHL)
- Testicular Cancer (Parent)

Renames

Previous Name	New Name
Doxorubicin 90 mg/m2 CIV D1-3 + Ifosfamide 2500 mg/m2 D1-4 Q21D (Sarcoma)	Doxorubicin 75 mg/m2 CIV D1-3 + Ifosfamide 2500 mg/m2 D1-4 Q21D (AIM) (Sarcoma)

Billing & HCPCS Codes

Updates

Medication	HCPCS Codes
Doxycycline Intrapleural	J3490 per 100 mg
Zanidatamab-hrii IV	J9999 per 300 mg
Zenocutuzumab-zbco IV	J9999 per 375 mg